KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...
MELBOURNE Australia, 5 June 2018, AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate toward clinical development, is pleased to announce that it has secured agreements critical to the development of its lead therapeutic program, AD-214. Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing services.
Read Full Press Release from AdAlta (PDF)
Durham, North Carolina (April 15, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global cGMP contract development and...
Durham, North Carolina (April 1, 2024) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing...
KBI Biopharma, a JSR Life Sciences Company and leading global Contract Development and Manufacturing Organization (CDMO) has received six awards in...